CLINICAL_TRIALS
trial_result
· 2026-02-10
Clinical Trial Update: ADX-629 Therapy for Sjogren-Larsson Syndrome [Phase 1, Phase 2]
Summary
Clinical trial update indicates ADX-629 for Sjogren-Larsson syndrome is in Phase 1/2 and not currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Nebraska | Conditions: Sjogren-Larsson Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING